PMID- 20373256
OWN - NLM
STAT- MEDLINE
DCOM- 20100914
LR  - 20100407
IS  - 2040-3410 (Electronic)
IS  - 1369-7056 (Linking)
VI  - 13
IP  - 4
DP  - 2010 Apr
TI  - INCB-13739, an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for the 
      treatment of type 2 diabetes.
PG  - 266-75
AB  - INCB-13739, being developed by Incyte Corp, is a novel, first-in-class 
      11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor for the 
      potential treatment of metabolic disorders, including type 2 diabetes mellitus 
      (T2DM) and obesity. INCB-13739 has high selectivity for 11beta-HSD1 over other 
      dehydrogenases and glucocorticoid and mineralocorticoid receptors, with prolonged 
      pharmacodynamic activity and good pharmacokinetic/pharmacodynamic properties. 
      INCB-13739 demonstrated improved hepatic and peripheral insulin sensitivity with 
      a satisfactory reduction in fasting plasma glucose and cholesterol after 28 days 
      of treatment in patients with T2DM, with a dose-dependent weight loss, decrease 
      in triglyceride levels and an improvement in blood pressure. Clinical data 
      demonstrated that INCB-13739 had a better efficacy to tolerability ratio compared 
      with potential competitors. The unique differentiation of INCB-13739 is its 
      effects on both glucose and lipid parameters coupled with its effects on body 
      weight and hypertension. The results from phase III clinical trials will be 
      pivotal; however, the available data suggest that INCB-13739 has potential for 
      success in the market.
FAU - Tiwari, Atul
AU  - Tiwari A
AD  - Jubilant Biosys Ltd, Drug Discovery Unit 96, 2nd Stage, Industrial Suburb, 
      Bangalore, India. atul_tiwari@jubilantbiosys.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - IDrugs
JT  - IDrugs : the investigational drugs journal
JID - 100883655
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - EC 1.1.1.146 (11-beta-Hydroxysteroid Dehydrogenase Type 1)
SB  - IM
MH  - 11-beta-Hydroxysteroid Dehydrogenase Type 1/*antagonists & inhibitors
MH  - Animals
MH  - Clinical Trials as Topic
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Enzyme Inhibitors/adverse effects/chemistry/pharmacokinetics/*therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents
RF  - 103
EDAT- 2010/04/08 06:00
MHDA- 2010/09/15 06:00
CRDT- 2010/04/08 06:00
PHST- 2010/04/08 06:00 [entrez]
PHST- 2010/04/08 06:00 [pubmed]
PHST- 2010/09/15 06:00 [medline]
PST - ppublish
SO  - IDrugs. 2010 Apr;13(4):266-75.